Virological and clinical implications of resistance to HIV-1 protease inhibitors

Drug Resistance Updates

Volumn 1, Issue 5, 1998, Pages 292-299

  Condra, Jon H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000130125     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(98)80045-9     Document Type: Review

References (50)

1. Wei X.P., Ghosh S.K., Taylor M.E., et al. Viral dynamics in human-immunodeficiency-virus type-1 infection. Nature 373 (1995) 117-122
2. Ho D.D., Neumann A.U., Perelson A.S., et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373 (1995) 123-126
3. Mansky L.M., and Temin H.M. Lower in-vivo mutation-rate of human-immunodeficiency-virus type-1 than that predicted from the fidelity of purified reverse-transcriptase. J Virol 69 (1995) 5087-5094
4. Coffin J.M. HIV Population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267 (1995) 483-489
5. Condra J.H., Schleif W.A., Blahy O.M., et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374 (1995) 569-571
6. Condra J.H., Holder D.J., Schleif W.A., et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type-1 protease inhibitor. J Virol 70 (1996) 8270-8276
7. Molla A., Korneyeva M., Gao Q., et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Medicine 2 (1996) 760-766
8. Jacobsen H., Hanggi M., Ott M., et al. In vivo resistance to a human-immunodeficiency virus type-1 proteinase-inhibitor-mutations, kinetics, and frequencies. J Infect Dis 173 (1996) 1379-1387
9. Patick A.K., Duran M., Cao Y., et al. Genotypic and phenotypic characterization of HIV-1 variants isolated from in vitro selection studies and from patients treated with the protease inhibitor, nelfinavir. Antivir Ther 1 Supplement 1 (1996) 17-18
10. Patick A.K., Markowitz M., Appelt K., et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human-immunodeficiency-virus protease. Antimicrob Agents Chemother 40 (1996) 292-297
11. Abstract #24. Markland W., Zuchowski L., Black J., et al. Kinetic and structural analysis of HIV-1 protease mutations: amprenavir resistance, cross-resistance, and resensitization. 2nd International Workshop on HIV Drug Resistance and Treatment Strategies. June 24-27, 1998, Lake Maggiore, Italy (1998) 19
12. Abstract # 32312. Tisdale M., Myers R.E., and Snowdon W. Genotypic and phenotypic analysis of HIV from patients on ZDV/3TC/amprenavir combination therapy. 12th World AIDS Conference. June 28-July 3, 1998, Geneva, Switzerland (1998)
13. Abstract # 10. Patick A.K., Duran M., Cao Y., et al. Genotypic analysis of HIV-1 variants isolated from patients treated with the protease inhibitor nelfinavir, alone or in combination with d4T or AZT and 3TC. 4th Conference on Retroviruses and Opportunistic Infections. Jan 22-26, 1997, Washington, D.C. (1997) 66
14. Condra JH, Holder DJ, Schleif WA et al. unpublished data.
15. Markowitz M., Mo H.M., Kempf D.J., et al. Selection and analysis of human-immunodeficency-virus type-1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 69 (1995) 701-706
16. Schmit J.C., Ruiz L., Clotet B., et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 10 (1996) 995-999
17. Winters M.A., Schapiro J.M., Lawrence J., and Merigan T.C. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. J Virol 72 (1998) 5303-5306
18. Tisdale M., Myers R.E., Maschera B., et al. Cross-resistance analysis of human-immunodeficiency-virus type-1 variants individually selected for resistance to 5 different protease inhibitors. Antimicrob Agents Chemother 39 (1995) 1704-1710
19. Smith T., and Swanstrom R. Selection for high-level resistance to HIV-1 protease inhibitors used in pairs. Antivir Ther 1 Supplement 1 (1996) 12-13
20. Abstract #71. De Pasquale M.P., Murphy R., Kuritzkes D., et al. Resistance during early virological rebound on amprenavir plus zidovudine plus lamividine triple therapy or amprenavir monotherapy in ACTG protocol 347. 2nd International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, Italy (1998) 50-51
21. Patick A.K., Boritzki T.J., and Bloom L.A. Activities of the human-immunodeficiency-virus type-1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse-transcriptase and protease inhibitors against acute HIV-1 infection in-vitro. Antimicrob Agents Chemother 41 (1997) 2159-2164
22. Poster # 600. Race E., Sheldon J.G., Kaye S., et al. Mutations associated with reduced sensitivity to saquinavir occur in a minority of patients treated in combination with ddC: Results from a phase III clinical trial (NV 14256). 4th Conference on Retroviruses and Opportunistic Infections. Washington, D.C. (1997) 175
23. Partaledis J.A., Yamaguchi K., Tisdale M., et al. In-vitro selection and characterization of human-immunodeficiency-virus type-1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 69 (1995) 5228-5235
24. Abstract # 406a. De Pasquale M.P., Murphy R., Gulick R., et al. Mutations selected in HIV plasma RNA during 141W94 therapy. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL (1998) 155
25. Kozal M.J., Shah N., Shen N.P., et al. Extensive polymorphisms observed in HIV-1 clade-B protease gene using high-density oligonucleotide arrays. Nature Medicine 2 (1996) 753-759
26. Erickson J.W., and Burt S.K. Structural mechanisms of HIV drug resistance. Ann Rev Pharmacol Toxicol (1996)
27. Wlodawer A., Miller M., Jaskolski M., et al. Conserved folding in retroviral proteases-crystal-structure of a synthetic HIV-1 protease. Science 245 (1989) 616-621
28. Navia M.A., Fitzgerald P.M.G., McKeever B.M., et al. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 337 (1989) 615-620
29. Collins J.R., Burt S.K., and Erickson J.W. Flap opening in HIV-1 protease simulated by 'activated' molecular dynamics. Nature Struct Biol 2 (1995) 334-338
30. Schock H.B., Garsky V.M., and Kuo L.C. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical-trials - compensatory modulations of binding and activity. J Biol Chem 271 (1996) 31957-31963
31. Vacca J.P., Dorsey B.D., Schleif W.A., et al. L-735,524 - an orally bioavailable human- immunodeficiency-virus type-1 protease inhibitor. Proc Nat Acad Sci USA 91 (1994) 4096-4100
32. Ho D.D., Toyoshima T., Mo H.M., et al. Characterization of human-immunodeficiency-virus type-1 variants with increased resistance to a c-2-symmetrical protease inhibitor. J Virol 68 (1994) 2016-2020
33. Maschera B., Tisdale M., Darby G., et al. In vitro growth characteristics of HIV-1 variants with reduced sensitivity to saquinavir explain the appearance of L90M escape mutants in vivo. Antivir Ther 1 Supp. 1 (1996) 53
34. Rayner M.M., Cordova B., and Jackson D.A. Population-dynamics studies of wild-type and drug-resistant mutant hiv in mixed infections. Virology 236 (1997) 85-94
35. Abstract 47. Condra J.H., Holder D.J., Graham D.J., et al. Genotypic or phenotypic susceptibility testing may not predict clinical responses to indinavir. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St. Petersburg, FL (1997) 31-32
36. Kaufmann D., Pantaleo G., Sudre P., and Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 351 (1998) 723-724
37. Abstract # 419. Deeks S., Beatty G., Cohen P.T., Grant R., and Volberding P. Viral load and CD4 + cell changes in patients failing potent protease inhibitor therapy. 5th Conference on Retroviruses and Opportunistic Infections. Feb. 1-5, 1998, Chicago, IL (1998) 158
38. Abstract # 110. Nijhuis M., Boucher C., de Jong D., et al. Enzymatic basis for increased replication kinetics of ritonavir resistant HIV-1 protease. 2nd International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, Italy (1998) 76
39. Doyon L., Croteau G., Thibeault D., et al. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 70 (1996) 3763-3769
40. Zhang Y.M., Imamichi H., Imamichi T., et al. Drug-resistance during indinavir therapy is caused by mutations in the protease gene and in its gag substrate cleavage sites. J Virol 71 (1997) 6662-6670
41. Doyon L., Payant C., Brakier-Gingras L., and Lamarre D. Novel gag-pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors. J Virol 72 (1998) 6146-6150
42. Abstract 15. Smith T., and Swanstrom R. Biological cross-resistance to HIV-1 protease inhibitors. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St. Petersburg, FL (1997) 10
43. Abstract # 70. Hertogs K., Kemp S., Bloor S., et al. Patterns of cross-resistance among protease inhibitors in over 1500 clinical HIV-1 isolates. Comparison of genotypic and phenotypic resistance profiles. 2nd International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, Italy (1998) 49-50
44. Abstract # 21. Para M.F., Collier A., Coombs R., et al. ACTG 333: antiviral effects of switching from saquinavir hard capsule (SQVhgc) to saquinavir soft gelatin capsule (SQV sgc) vs. switching to indinavir (IDV) after prior saquinavir. Infectious Disease Society of America 35th Annual Meeting. San Francisco, CA (1997) 75
45. Abstract 64. Lawrence J., Schapiro J., Pesano R., et al. Clinical response and genotypic resistance patterns of sequential therapy with nelfinavir followed by indinavir plus nevirapine in saquinavir/reverse transcriptase inhibitor-experienced patients. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St. Petersburg, FL (1997) 42
46. Abstract 87. Schapiro J., Winters M., Lawrence J., et al. Clinical and genotypic cross-resistance between the protease inhibitors saquinavir and indinavir. International Workshop on HIV Drug Resistance, Treatment Strategies, and Eradication. St. Petersburg, FL (1997) 57
47. Abstract A-17. Rachlis A.R., Palmer R.H., Bast M., et al. Predictors of decreases in plasma HIV-1 RNA in patients treated with indinavir. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario (1997)
48. Abstract I-204. Henry K., Kane E., Melroe H., et al. Experience with a ritonavir/saquinavir based regimen for the treatment of HIV infection in subjects developing increased viral loads while receiving nelfinavir. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario (1997)
49. Abstract LB-5. Sampson M.S., Barr M.R., Torres R.A., and Hall G. Viral load changes in nelfinavir treated patients switched to a second protease inhibitor after loss of viral suppression. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario (1997)
50. Program Supplement. Condra J.H., Holder D.J., Schleif W.A., et al. Bi-directional inhibition of HIV-1 drug resistance selection by combination therapy with indinavir and reverse transcriptase inhibitors. Abstract # Th.B.932. XI International Conference on AIDS. Vancouver, B.C. (1996) 19